Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis

Authors:

Abstract
Sir, Erdheim–Chester disease (ECD) is a rare (approximately 350 published cases worldwide) non-Langerhans cell histiocytosis (LCH) characterized by tissue infiltration with CD68+, CD1a− foamy histiocytes. The disease almost invariably affects bones, causing the nearly pathognomonic osteosclerosis of the limbs. In addition, ECD patients frequently have extra-skeletal manifestations, including exophthalmos, xanthelasma, interstitial lung disease, retroperitoneal fibrosis, pituitary and hypothalamic infiltration and central nervous system and cardiovascular involvements [1–3]. IFN-α represents the best available treatment [4], but response to therapy varies among patients and according to the sites of involvement [5].

This publication has 10 references indexed in Scilit: